Rutherford Health - Clinical Trials Collaboration with Panthera London Stock Exchange
RNS Number : 9544Q
Rutherford Health PLC
24 June 2020

24 June 2020





Rutherford Health plc (the "Company" or "Group" or "Rutherford") is delighted to announce that it has formed a collaboration with Panthera Biopartners Ltd ("Panthera"), an independent site management organisation (SMO).

Under the terms of the agreement, Rutherford will host clinical trials, organised by Panthera on behalf of its pharmaceutical and contract research organisation clients,  of emerging cancer treatments at the Company's cancer centres in the UK.

The collaboration, called Panthera@theRutherford, combines Panthera's expertise in managing and running clinical trials with Rutherford's network of centres and leading oncologists.  

Rutherford's network consists of four cancer treatment in Newport, Reading, Bedlington and Liverpool* and will draw patients from all over the UK offering Pharma and CROs access to patients through more than 170 referring oncologists.

Mike Moran, CEO Rutherford Health PLC commented "We are delighted to partner with Panthera to undertake professional cancer research in our centres. We will be at the forefront of research into innovative therapies and we'll be able offer more opportunities to patients and access to life-saving treatments."

Dr Ian Smith, Chief Medical Officer of Panthera, commented: 

"This really is a breakthrough partnership. Over 30% of all global clinical trials planned for 2020 are cancer trials; bringing research and cancer care together in one place will provide pharma and CROs the opportunity to undertake clinical trials with unrivalled access to more than 40 types of cancer and have access to  potential patients when there is a great shortage of top class sites."

*  opening Summer 2020

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

The directors of Rutherford Health plc accept responsibility for this announcement.


Rutherford Health plc



Michael Moran, Chief Executive Officer

Tel: +44 (0) 16 3381 0661





Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100


Colin Aaronson / Niall McDonald






Media House International   

07788 414 856 or 0207 710 0020


Ramsay Smith




About Rutherford Health

Rutherford Health  plc Rutherford Health plc is the UK incorporated holding company of a group committed to providing innovative cancer care of the highest quality. The Group's oncology centres in the UK, named The Rutherford Cancer Centres, offer a comprehensive range of cancer treatments to patients including proton beam therapy ("PBT"), conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services. The company was founded in 2015 by Mike Moran and UK and international cancer experts, including Professor Karol Sikora, former head of the World Health Organisation's cancer programme.

The Rutherford Cancer Centres feature the most advanced technologies and Rutherford Health Plc has formed a partnership with IBA (Ion Beam Applications), the world's leading provider of proton beam therapy solutions and Philips, a leader in health technology.

All centres offer proton beam therapy to medically-insured private patients, self-paying patients and NHS patients where the Rutherford is commissioned to provide these services.

Follow the Rutherford Cancer Centres on twitter: @therutherford_c


About Panthera Biopartners

Panthera Biopartners - an Independent Site Management Organisation

Panthera Biopartners was founded by Dr Ian Smith - founder of Synexus - and Professor John Lyon - previously senior executive in Covance and serial entrepreneur - in July 2019 to provide CROs and pharma clients with services relating to the recruitment and running of clinical trials at customised clinical trial sites by GCP trained healthcare professionals.

The first Panthera site was opened in Preston, UK in November 2019. Today, Panthera has a growing network of its own sites across the UK managing studies in a variety of conditions in both primary care settings and hospital sites running trials in key secondary care conditions such as CNS, oncology and NASH with specialist investigators.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit